佛慈制药第三季度净利润增长167.92%，切入放射性同位素药物新赛道

Group 1 - The core viewpoint is that 佛慈制药 (Fuzhi Pharmaceutical) has experienced a significant year-on-year net profit growth of 167.92% in the third quarter, alongside a notable improvement in operating cash flow. The company is also entering the radioactive isotope drug sector and expanding into the precision medicine field [1] - Market attention towards 佛慈制药 is currently moderate, with overall sentiment being neutral. The forecast for net profit growth in 2025 is projected at 52.11%, although the valuation remains high with a PE TTM of approximately 77.45 times [1] - The recent release of the new National Essential Medicines List may provide policy benefits for the traditional Chinese medicine sector, which could indirectly impact 佛慈制药 [2] Group 2 - In the past seven trading days, 佛慈制药's stock price has shown limited volatility, with the latest closing price on February 13, 2026, at 8.96 yuan, reflecting a decline of 1.65% on that day and a cumulative drop of 6.96% over five days [3] - On February 13, 2026, there was a net inflow of 6.1033 million yuan in main funds, but the overall technical indicators suggest that the stock is in a bearish trend, underperforming compared to the broader market and industry averages [3]